# RESEARCH

**BMC Pulmonary Medicine** 

**Open Access** 



Qiaofeng Li<sup>1†</sup>, Yandong Zhao<sup>2†</sup>, Zheng Xu<sup>1</sup>, Yongqing Ma<sup>1</sup>, Chengyu Wu<sup>1\*</sup> and Huayue Shi<sup>1\*</sup>

# Abstract

**Background** This study was to establish and validate prediction models to predict the cancer-specific survival (CSS) and overall survival (OS) of small-cell lung cancer (SCLC) patients with liver metastasis.

**Methods** In the retrospective cohort study, SCLC patients with liver metastasis between 2010 and 2015 were retrospectively retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were randomly divided into the training group and testing group (3: 1 ratio). The Cox proportional hazards model was used to determine the predictive factors for CSS and OS in SCLC with liver metastasis. The prediction models were conducted based on the predictive factors. The performances of the prediction models were evaluated by concordance indexes (C-index), and calibration plots. The clinical value of the models was evaluated by decision curve analysis (DCA).

**Results** In total, 8,587 patients were included, with 154 patients experiencing CSS and 154 patients experiencing OS. The median follow-up was 3 months. Age, gender, marital status, N stage, lung metastases, multiple metastases surgery of metastatic site, chemotherapy, and radiotherapy were independent predictive factors for the CSS and OS of SCLC patients with liver metastasis. The prediction models presented good performances of CSS and OS among patients with liver metastasis, with the C-index for CSS being 0.724, whereas the C-index for OS was 0.732, in the training set. The calibration curve showed a high degree of consistency between the actual and predicted CSS and OS. DCA suggested that the prediction models provided greater net clinical benefit to these patients.

**Conclusion** Our prediction models showed good predictive performance for the CSS and OS among SCLC patients with liver metastasis. Our developed nomograms may help clinicians predict CSS and OS in SCLC patients with liver metastasis.

Keywords Prognostic models, Small cell lung cancer patients, Liver metastasis, Nomogram, SEER database

<sup>†</sup>Qiaofeng Li and Yandong Zhao are co first author.

\*Correspondence: Chengyu Wu 290045@njucm.edu.cn Huayue Shi moonshy1988@njucm.edu.cn Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.gr/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.gr/licenses/by/4.0/.

# Background

Lung cancer is one of the most common malignancies, and its morbidity and mortality are increasing worldwide [1, 2]. Small-cell lung cancer (SCLC) is a type of aggressive malignancy with rapid growth and early metastasis, accounting for between 10 and 15% of all lung cancer diagnoses [3]. Approximately two-thirds of SCLC patients have obvious metastasis at the time of clinical diagnosis [4]. Liver metastasis is one of the frequent metastatic sites of SCLC [5, 6]. SCLC patients with liver metastasis tend to have a worse prognosis, with the one-year survival rate being less than 20% [5, 7]. Identifying the prognostic factors of SCLC patients with liver metastasis and improving the prognosis of patients is currently needed.

Few studies have investigated the prognostic factors of SCLC with metastasis, although several studies have focused on the survival outcomes of patients with SCLC [8, 9]. According to a study, age was revealed to be a significant predictor of overall survival (OS) in SCLC patients with distant metastases [10]. Based on the study by Cheng et al., targeted therapy may play a significant role in improving patient prognosis in SCLC with liver metastases [11]. The factors associated with OS and cancer-specific survival (CSS) of the SCLC with liver metastasis warrant further investigation. The clinical prediction model is a significantly important tool that can stratify patients before treatment to determine whether a specific treatment scheme is worthy of implementation, which has been widely used in clinical practice [12]. Recently several prediction models have been developed to predict the survival in SCLC [9, 13, 14]. Nevertheless, most of the previous prediction models focused on early-stage, III-stage, and N2-stage SCLC [13, 15]. There is a scanty study focusing on the prognosis of liver metastasis in patients with SCLC [12]. Given the high mortality rate following liver metastases from SCLC and the various clinical characteristics of different patients with SCLC, prediction models for the prognosis in SCLC patients with liver metastases are imperative.

Herein, we investigated the factors associated with survival of SCLC with liver metastasis using a large cohort from the Surveillance, Epidemiology, and End Results (SEER) database and developed prediction models to predict their CSS and OS. Besides, we also verified the prediction models using internal validation and performed a series of tests to evaluate the performances of predictive models. The development of prediction models may enable a better treatment stratification for SCLC patients with liver metastasis.

# Methods

# Study design and participants

The retrospective cohort study was based on the SEER program which covers approximately 30% of the total US population [16]. The records of SCLC patients with liver metastasis between 2010 and 2015 were extracted from the database 'SEER 18 Regs Custom Data (including additional treatment fields), November 2018 sub (1975-2016 varying) database using SEER\*stat 8.3.5 software. The International Classification of Diseases for Oncology third edition (ICD-O-3) was used to identify SCLC by site codes [8002, 8041, 8043, 8144, 8145] [17]. The inclusion criteria were as follows: (I) SCLC was the only primary cancer; (II) the staging of lymph nodes followed the 7th edition of the American Joint Committee on 2 Journal of International Medical Research Cancer; (III) aged  $\geq$  18 years old; (IV) patients with liver metastasis [SEER Combined Mets at DX-liver (2010+)]. Since the clinical data in this study were collected from a publicly available database, there were no local or state ethical issues. In addition, because this retrospective study was based on public data from the SEER database, informed consent was not required. All methods were performed in accordance with the relevant guidelines and regulations.

### Study variables and outcomes

The database reviewed retrospectively consisted of clinical characteristics of patients, pathological characteristics of tumors, and survival time (months). Continuous variables were transformed into categorical variables based on recognized cut-off values (for age). Clinical characteristics of patients included gender (female vs male), age  $(\leq 65 \text{ years}, > 65 \text{ years})$ , race (black, white, and other), and marital status (married and other). Pathological characteristics of tumors include primary site [multiple sites, upper lobe, middle lobe, lower lobe, main bronchus, not otherwise specified (NOS)], tumor size ( $\leq 24$  mm, 25–37 mm, 38–59 mm,  $\geq$  60 mm), T stage in 7th edition AJCC system [T1, T2, T3, T4, and not specific known T stage (Tx)], N stage in 7th edition AJCC system [N1, N2, N3, N4, and not specific known N stage (Nx)], metastatic sites (bone, brain, lung, multiple other metastases, no metastases or unknown), surgery of primary site or not/ unknown, surgery of metastatic site or not/unknown, radiotherapy or not/unknown, chemotherapy or not/ unknown. The outcomes in this study were 1- and 2-year CSS and 1- and 2-year OS. The classification of tumor size was based on the inter-quartiles ranges. The outcomes in this study were 1- and 2-year CSS and 1- and 2-year OS. CSS was defined as the time between diagnosis and death owing to specific cancer during follow-up and OS was defined as death regardless of any causes. The total observation period was 2 years; follow-up would terminate if the patient died. The median followup time was 3 months.

# Development and validation of the prediction models

For the development of the nomograms, all of the 8,587 cases were randomly divided into the training set and test set (ratio: 3:1) by using the random-number generation method. The prediction models were established on the basis of the predictive factors identified by Cox proportional hazards model. The performances of the prediction models were evaluated by measuring the concordance index (C-index), calibration plots, and decision curve analysis (DCA).

# Statistical analysis

Measurement data by normal distribution are described in mean  $\pm$  standard deviation (Mean  $\pm$  SD). The independent

sample t-test or analysis of one-way variance (ANOVA) was used for comparisons between groups. Non-normal data were described as a median and interquartile range [M ( $Q_1$ ,  $Q_3$ )], and the Mann–Whitney U test or Kruskal–Wallis test was applied for comparisons between groups. Enumeration data were described as the number of cases and the constituent ratio [N (%)]. The Chi-square test was used for comparison between groups.

Hazard ratios (HRs) and their 95% confidence intervals (CIs) for each potential predictive variable were analyzed using Cox proportional risk models. The variables with multiple categories were transformed into dummy variables before further analyses. False-discovery rate (FDR) adjusted P values were calculated to correct for multiple testing. Based on the predictive factors, prediction models were conducted to predict the 1- and 2-year CSS and OS. The performances of the final nomogram were assessed by C-index, and calibration measures as the measuring tool. The C-index is a concordance measure analogous to ROC, which values range from



Fig. 1 The flow chart of patient's selection

# Table 1 Demographic and clinical characteristics in SCLC patients with liver metastasis

Age, n. (%), years         565         3770 (43.50)         2796 (43.42)         974 (45.57)           >55         4817 (60.10)         3644 (56.58)         1173 (44.53)           Cender, n%)         Emrale         1173 (44.637)           Fernale         3988 (46.44)         2947 (45.76)         1041 (48.49)           Male         4599 (53.56)         3493 (54.24)         1106 (51.51)           Race, n%)          1173 (88.99)         1388 (88.40)           Other         726 (83.44)         731 (88.99)         1388 (88.40)           Other         4300 (50.8)         3273 (50.65)         1077 (63.6)           Martial Status, n (%)           1077 (53.6)           Martial Status, n (%)          1077 (53.6)         307 (13.2)           Upper lobe         269 (43.67)         2797 (43.43)         901 (41.97)           Multiple         134 (15.6)         5 (1.48)         572 (25.5)           Lowerlobe         269 (43.67)         2797 (43.43)         901 (41.97)           Multiple         134 (15.6)         132 (25.3)         442 (25.8)           Lowerlobe         269 (43.67)         2797 (43.43)         901 (41.97)           Multiple         1332 (21.02)         1332	Variables	Total (n = 8,587)	Training set ( <i>n</i> = 6,440)	Testing set ( <i>n</i> = 2,147)	
	Age, n (%), years				
> As4817 (A.10)3644 (A.28)11.7 (A.4.3)Gender, n (%)-Fanale3988 (Ab.44)2947 (45.76)1041 (48.49)Male496 (35.56)2943 (54.24)1106 (51.51)Baca, n (%)-172 (80.19)172 (80.19)White295 (35.4)218 (33.9)173 (39.10)Others295 (34.4)218 (33.9)173 (39.10)Marila Istata, n (%)-100 (49.24)100 (49.24)Umary sites, n (%)-95 (1.48)90 (1.19,7)Maring134 (1.56)95 (1.48)90 (1.19,7)Multiple134 (1.56)205 (1.51)205 (1.61)Upper lohe306 (40.77)277 (13.43)01 (11.97)Multiple138 (20.11)139 (20.33)444 (20.68)Main bronchus297 (10.31)137 (20.11)57 (25.51)Lower lobe103 (20.10)133 (20.10)470 (11.89)Umor loses, n (%)470 (11.89)Conder, n (%)470 (20.11)2-34 run218 (25.54)164 (25.59)54 (25.30)38-30 run2174 (25.32)151 (25.22)54 (25.30)38-30 run2174 (25.32)161 (25.37)54 (25.30)2-34 run103 (11.67)105 (12.57)105 (12.57)100 (10.21)7110105 (12.2)77 (12.90)104 (12.31)11104 (25.37)153 (12.63)423 (10.70)12153 (12.63)139 (11.63)140 (21.91)1410.30 (13.64) </td <td>≤65</td> <td>3770 (43.90)</td> <td>2796 (43.42)</td> <td>974 (45.37)</td>	≤65	3770 (43.90)	2796 (43.42)	974 (45.37)	
Gender, n%)UUUFemale368 (64.4)493 (54.24)104 (64.69)Male4599 (53.56)4943 (54.24)106 (51.51)Back, n (%)V118 (63.90)1898 (88.40)Others262 (88.84)57.11 (88.99)1898 (88.40)Others265 (3.44)121 (63.90)1898 (88.40)Others262 (88.84)2213 (50.05)1077 (50.16)Martial stars, n (%)2117 (49.59)1077 (63.63)Martial stars, n (%)1071 (63.93)39 (18.21)Mutiple369 (63.07)257 (43.33)39 (18.21)Others369 (63.07)257 (43.33)39 (18.21)Mutiple369 (63.07)270 (63.83)270 (63.93)Main bornchus97 (10.91)701 (10.89)236 (10.99)NoS180 (21.00)133 (20.70)23 (10.99)NoS180 (21.01)134 (22.37)59 (23.71)Lower labe97 (10.91)701 (10.89)25 (10.93)NoS180 (21.22)163 (25.29)50 (13.71)25 37 mm218 (25.43)1644 (25.37)50 (25.2)26 0 mm218 (25.43)1644 (25.37)50 (25.2)26 0 mm218 (25.43)1644 (25.37)50 (25.2)27 taage, n(%)1180 (18.32)42 (13.9)42 (13.9)17 Laage, n(%)1180 (18.22)42 (13.9)42 (13.9)17 Laage, n(%)1180 (18.22)42 (13.9)42 (13.9)18 (14.64)139 (14.67)140 (13.9)42 (13.9)17 Laage, n(%)1180 (18.32)<	>65	4817 (56.10)	3644 (56.58)	1173 (54.63)	
Fenda         398 (46.4)         2947 (45.7a)         104 (148.49)           Male         499 (53.5c)         3493 (54.24)         1106 (51.51)           Back         0.63 (7.72)         4943 (54.24)         172 (80.7)           Male         2059 (53.46)         573 (89.99)         172 (80.7)           White         2059 (34.4)         18 (83.90)         77 (33.9)           Marital Satus, n (%)         5223 (50.05)         1077 (50.16)           Married         4207 (49.92)         3217 (49.95)         1070 (49.84)           Upper labe         4200 (50.08)         5223 (50.05)         1070 (49.84)           Upper labe         4297 (49.92)         2217 (49.95)         1070 (49.84)           Upper labe         263 (30.7)         2797 (43.43)         901 (41.97)           Upper labe         262 (30.5)         263 (31.0)         236 (10.99)           Main bronchus         927 (10.91)         701 (10.89)         276 (10.91)           NOS         1838 (21.00)         133 (27.00)         426 (25.91)           Signes, n (%)	Gender, n (%)				
Male4999 (33.50)3939 (34.24)1100 (51.51)Race, r (%)Race, r (%)Whre729 (98.84)Others259 (34.40)Warial staus, n (%)Warial staus, n (%)Warial staus, n (%)Witzer, r (%)Upper lobe3696 (430.7)V (10.59)257 (43.3)Middle lobe262 (3.05)Low r lobe3697 (43.1)Middle lobe3693 (21.00)NoS1833 (21.00)V (30.51)361 (25.7)V (30.52)1833 (21.00)NoS1939 (25.54)All staus, n (%)U1939 (25.54)V (30.52)1631 (25.37)Sa 50 mm2164 (25.37)25.37 mm2198 (25.42)161 (25.22)1631 (25.32)17 Ta165 (12.22)Ta169 (13.62)17 Au1930 (13.63)1840 (25.7)154 (25.83)1840 (25.7)154 (17.91)1840 (13.1)1892 (13.31)1840 (13.1)1892 (13.31)1840 (13.1)1892 (13.31)1840 (13.1)1893 (14.63)1840 (13.1)1893 (14.63)1840 (13.24)120 (63.12) <td>Female</td> <td>3988 (46.44)</td> <td>2947 (45.76)</td> <td>1041 (48.49)</td>	Female	3988 (46.44)	2947 (45.76)	1041 (48.49)	
Bace, n (%)         U         I/262           Black         650 (28,84)         5731 (88,99)         1728 (30)           Others         295 (3.4)         218 (3.39)         7 (3.59)           Marital staus, n (%)         2223 (50.05)         077 (50.16)           Marital staus, n (%)         277 (43.43)         39 (1.82)           Upper lobe         263 (0.37)         2797 (43.43)         442 (0.08)           Main bronchus         263 (0.01)         1330 (20.02)         260 (0.02)           NoS         1803 (2.101)         1309 (20.33)         444 (20.89)           NoS         1803 (2.102)         132 (2.72)         260 (0.22)           So (30.02)         1803 (2.102)         1634 (2.5.39)         569 (2.3.02)           25-37 mm         2193 (2.5.4)         1644 (2.5.37)         590 (2.5.2)           260 nm         2184 (2.5.4)         1634 (2.5.30)         261 (3.02)           714 (3.1)         601 (7.5)         71 (1	Male	4599 (53.56)	3493 (54.24)	1106 (51.51)	
Back         633 (7.7)         491 (7.62)         172 (80.1)           White         7529 (88.44)         7531 (88.59)         1896 (88.40)           Others         255 (4.4)         283 (35.3)         177 (5.9)           Married         4300 (50.08)         3223 (50.5)         1077 (50.16)           Married         4300 (50.8)         3223 (50.5)         1077 (01.49.8)           Primary sites, n (%)	Race, n (%)				
White         729 (88.84)         573 (88.99)         1898 (88.40)           Others         295 (3.44)         28 (3.3)         77 (3.5)           Wirtal status, n(%)         3222 (50.05)         1077 (50.16)           Marrid         49.00 (50.08)         3222 (50.05)         1077 (50.16)           Marrid         49.01 (49.22)         3217 (49.95)         1077 (50.16)           Marrid         49.01 (49.27)         2797 (43.43)         901 (41.97)           Middle lobe         262 (0.5)         205 (3.18)         77 (2.5.9)           Lower lobe         173 (20.41)         1309 (20.33)         444 (20.08)           Middle lobe         262 (0.05)         203 (20.70)         236 (10.99)           NOS         1803 (21.00)         1332 (20.70)         236 (10.99)           Tomor stess, n(%)         1527 (23.71)         509 (23.71)         509 (23.71)           Comman         2134 (25.43)         1634 (25.37)         550 (25.62)           25-37 mm         2133 (25.41)         1634 (25.37)         550 (25.62)           26 mm         2144 (25.43)         1634 (25.37)         550 (25.62)           38-50 mm         2144 (25.43)         1634 (25.37)         560 (25.62)           154 (25.80)         154 (25.32)	Black	663 (7.72)	491 (7.62)	172 (8.01)	
Others         295 (3.4)         218 (3.39)         77 (3.59)           Marilat Satus, n (%)	White	7629 (88.84)	5731 (88.99)	1898 (88.40)	
Married         Second Sec	Others	295 (3.44)	218 (3.39)	77 (3.59)	
Other         4300 (50.08)         3223 (50.05)         1077 (50.16)           Maried         227 (4992)         317 (4995)         1077 (69.494)           Pirmary sites, n(%)         341 (1.56)         95 (1.48)         39 (1.82)           Upper lobe         3698 (43.07)         205 (3.18)         57 (2.65)           Middle lobe         205 (3.05)         205 (3.18)         57 (2.65)           Lower lobe         1753 (20.41)         1309 (20.33)         444 (20.88)           Mid bonchus         937 (10.91)         1333 (20.01)         205 (0.99)           No So         1803 (21.00)         1333 (20.01)         509 (23.71)           Turm sizes, n (%)         1527 (23.71)         509 (23.71)           Turm sizes, n (%)         1527 (23.71)         509 (23.71)           Sa S-39 mm         2164 (25.43)         1634 (25.57)         501 (25.62)           \$3 B-59 mm         2164 (25.43)         1631 (25.22)         501 (25.62)           \$3 S-59 mm         2164 (25.43)         1631 (25.22)         501 (25.62)           Tato         1603 (18.7)         110 (10.81)         220 (07.01)           Tata         280 (13.63)         410 (19.10)         230 (17.00)           Tato         1835 (13.61)         154 (17.92)	Marital status, n (%)				
Married         4287 (49.92)         3217 (49.95)         1070 (49.84)           Primary sites, n (%)	Other	4300 (50.08)	3223 (50.05)	1077 (50.16)	
Primary sites, n (%)         Multiple         134 (1.56)         95 (1.48)         39 (1.82)           Mupper labe         3698 (43.07)         2797 (43.43)         901 (41.97)           Middle lobe         26 (3.05)         205 (3.18)         57 (2.65)           Lower lobe         1733 (20.41)         1309 (20.33)         444 (20.68)           Main bronchus         937 (10.91)         701 (10.89)         236 (10.99)           NOS         1803 (21.00)         1333 (20.70)         470 (21.89)           Tumor sizes, n (%)         -         -         -         470 (21.89)           Soft mm         2036 (23.71)         1527 (23.71)         509 (23.71)           25-37 mm         2193 (25.54)         1634 (25.37)         550 (25.62)           25-37 mm         2194 (25.43)         1634 (25.37)         550 (25.62)           25-37 mm         2194 (25.43)         1634 (25.37)         550 (25.62)           26 0 mm         2174 (25.22)         77 (1.20)         28 (1.30)           T tagge, n (%)         T         1603 (18.67)         1180 (18.32)         432 (19.70)           T 4         2670 (23.42)         2165 (23.62)         705 (32.84)           T 4         2670 (23.42)         216 (53.62)         705 (32.84)	Married	4287 (49.92)	3217 (49.95)	1070 (49.84)	
Multiple         134 (1.56)         95 (1.48)         39 (1.82)           Upper lobe         3689 (3.37)         2797 (43.43)         901 (41.97)           Middle lobe         262 (3.05)         205 (3.18)         57 (2.65)           Lower lobe         175 (2.041)         1309 (20.33)         444 (2.06.8)           Main bronchus         937 (10.91)         701 (10.89)         236 (10.99)           NOS         1803 (21.00)         1309 (20.33)         444 (20.68)           Tumor sizes, n(%)	Primary sites, n (%)				
Upper lobe         3688 (43.07)         2797 (43.43)         901 (41.97)           Middle lobe         26 (3.05)         250 (3.18)         57 (2.65)           Lower lobe         1753 (20.41)         1309 (20.33)         444 (20.68)           Min bronchus         970 (0.91)         701 (10.89)         226 (10.99)           NOS         1803 (21.00)         1333 (20.70)         470 (21.89)           Tumor sizes, n (%)        24 mm         2036 (23.71)         1527 (23.71)         509 (23.71)           0-24 mm         2036 (23.71)         1648 (25.59)         545 (25.38)           38-59 mm         2193 (25.54)         1648 (25.57)         550 (25.62)           260 mm         2194 (25.43)         1631 (25.22)         550 (25.62)           260 mm         2194 (25.43)         1631 (25.27)         550 (25.62)           260 mm         1214 (25.43)         1631 (25.27)         550 (25.62)           260 mm         1291 (7.45)         1631 (25.27)         281 (25.9)           T2         1835 (21.37)         1932 (21.63)         422 (25.9)           T2         1835 (21.37)         1932 (21.63)         422 (25.9)           T4         2870 (33.42)         2156 (35.62)         755 (22.84)           T5	Multiple	134 (1.56)	95 (1.48)	39 (1.82)	
Middle lobe         262 (3.0.5)         205 (3.18)         57 (2.6.5)           Lower lobe         1753 (20.41)         1309 (20.33)         444 (20.68)           Main bronchus         937 (10.91)         701 (10.89)         236 (10.99)           NOS         1833 (20.00)         433 (20.70)         470 (21.89)           Tumor sizes, n (%)         -         -         -         -           0-24 mm         2036 (23.71)         1527 (23.71)         509 (23.71)           25-37 mm         2193 (25.54)         1648 (25.57)         550 (25.62)           ≥60 mm         2124 (25.32)         1631 (25.32)         543 (25.29)           T tage, n (%)         -         -         -         -           T 0         10S (12.2)         77 (1.20)         28 (1.30)           T 1         640 (7.45)         471 (7.31)         169 (7.87)           T 2         1835 (21.37)         1393 (21.63)         442 (20.59)           T 3         1603 (18.67)         1180 (18.20)         423 (19.70)           T x         1534 (17.86)         1154 (17.92)         380 (17.70)           N 1         597 (05.34)         1215 (56.59)         314 (4.61)           N 2         1596 (61.1         212 (98.7)	Upper lobe	3698 (43.07)	2797 (43.43)	901 (41.97)	
Lower lobe         175 (20.41)         1309 (20.33)         444 (20.68)           Main bronchus         937 (10.91)         701 (10.89)         226 (10.99)           NOS         1803 (21.00)         1333 (20.70)         470 (20.87)           Tumor sizes, n(%)         701 (10.89)         700 (20.371)         509 (23.71)           0-24 mm         0306 (23.71)         1527 (23.71)         509 (23.71)           25-37 mm         2134 (25.43)         1648 (25.59)         550 (25.62)           38-59 mm         2184 (25.43)         1634 (25.37)         550 (25.62)           38-60 mm         2174 (25.32)         1631 (25.37)         550 (25.62)           5 60 mm         015 (1.22)         77 (1.20)         28 (1.30)           T 1         640 (74.5)         71 (7.1)         169 (7.87)           T 2         1835 (21.37)         1393 (21.63)         422 (0.59)           T 3         1603 (18.67)         1180 (18.32)         423 (19.70)           T 4         237 (53.42)         154 (7.80)         154 (7.80)         154 (7.80)           N 4 state         Segm         399 (10.36)         678 (10.53)         121 (9.65)           N 1         519 (60.4)         529 (63.51)         144 (6.71)           N 2	Middle lobe	262 (3.05)	205 (3.18)	57 (2.65)	
Main bronchus         937 (10.91)         701 (10.80)         236 (10.99)           NOS         1803 (21.00)         1333 (20.70)         470 (21.89)           Tumor sizes, n (%)         -         -         -           0-24 mn         2036 (23.71)         1527 (23.71)         500 (23.71)           25-37 mn         2193 (25.54)         1648 (25.59)         545 (25.38)           38-59 mn         2184 (25.43)         1634 (25.37)         550 (25.62)           >60 mm         205 (12.2)         1631 (25.32)         543 (25.92)           T stage, n (%)         -         153 (27.37)         550 (25.62)           T stage, n (%)         -         105 (1.22)         77 (1.20)         28 (1.30)           T 1         640 (7.45)         471 (7.31)         169 (7.87)           T 2         1835 (21.37)         1930 (1.63)         422 (20.59)           T 3         1630 (18.67)         1180 (18.32)         423 (19.70)           T 4         2870 (33.42)         1165 (18.32)         230 (17.70)           N t age, n (%)         -         1180 (18.32)         212 (9.87)           N t age, n (%)         -         212 (9.87)         144 (6.71)           N 2 2 (5.56)         530 (5.5.34)         121 (5.6.5	Lower lobe	1753 (20.41)	1309 (20.33)	444 (20.68)	
NOS         1803 (21.00)         133 (2.00)         470 (21.89)           Tumor sizes, n (%)	Main bronchus	937 (10.91)	701 (10.89)	236 (10.99)	
Tumor sizes, n (%)         No.         No.           0-24 mm         2036 (23.71)         1527 (23.71)         509 (23.71)           25-37 mm         2193 (25.54)         1648 (25.37)         550 (25.62)           38-59 mm         2184 (25.43)         1634 (25.37)         550 (25.62)           a 60 mm         2174 (25.32)         1631 (25.32)         543 (25.29)           T stage, n (%)         77 (1.20)         28 (1.30)         169 (7.87)           T1         640 (7.45)         77 (1.731)         169 (7.87)           T2         1835 (21.37)         1393 (21.63)         442 (20.59)           T3         1603 (18.67)         1180 (18.32)         423 (19.70)           T4         2870 (33.42)         2165 (33.62)         705 (32.84)           Tx         1534 (17.86)         1154 (17.92)         380 (17.70)           N stage, n (%)         N         590 (6.04)         582 (16.35)         144 (6.71)           N2         4779 (55.65)         3564 (55.34)         1215 (56.59)           N3         1849 (21.53)         1399 (21.72)         450 (20.66)           Nx         550 (6.41)         424 (65.81)         126 (5.87)           Nx         550 (6.41)         424 (6.51)         46 (6.00) <td>NOS</td> <td>1803 (21.00)</td> <td>1333 (20.70)</td> <td>470 (21.89)</td>	NOS	1803 (21.00)	1333 (20.70)	470 (21.89)	
0-24 m2036 (23.71)1527 (23.71)509 (23.71)25-37 mm2193 (25.54)1648 (25.59)545 (25.38)38-59 mm2184 (25.33)1634 (25.37)550 (25.62)≥60 mm2184 (25.32)1634 (25.37)543 (25.29)T tatge, r0(b)77 (1.20)28 (1.30)T1640 (7.45)471 (7.31)169 (7.87)T21835 (21.37)1393 (21.63)422 (05.9)T31603 (18.67)1180 (18.32)423 (19.70)T42870 (33.42)216 (33.62)705 (32.84)Tx1534 (17.86)1154 (17.92)380 (17.70)Nage, n(%)1154 (17.92)380 (17.70)N tatge, n(%)519 (6.04)524 (6.35)144 (6.71)N24779 (55.65)3564 (55.34)1215 (56.59)N31849 (21.53)1399 (21.72)450 (20.96)Nx550 (6.41)424 (6.58)124 (5.87)Metatatic lesion, n(%)159 (24.83)554 (25.80)Brain565 (55.8)419 (6.51)146 (6.80)Lung729 (8.49)537 (8.34)192 (8.94)Multiple metastases1527 (17.8)1147 (17.81)380 (17.70)No or unknown853 (99.60)6414 (99.60)2139 (99.63)Vers34 (0.40)26 (0.40)80.37Surgery of primary site, n(%)1147 (17.81)80.01,70No/unknown853 (99.60)6414 (99.60)2139 (99.63)Vers34 (0.40)26 (0.40)80.37Surgery of primary site, n(%)1147 (17.81)80	Tumor sizes, n (%)				
25-37 mm         2193 (25.4)         1648 (25.9)         545 (25.3)           38-59 mm         2184 (25.43)         1634 (25.37)         550 (25.62)           > 60 mm         2174 (25.32)         1631 (25.32)         543 (25.29)           T stage, n (%)	0–24 mm	2036 (23.71)	1527 (23.71)	509 (23.71)	
38-59 mm         2184 (25.43)         1634 (25.37)         550 (25.62)           ≥ 60 mm         2174 (25.32)         1631 (25.32)         543 (25.29)           T stage, n (%)	25–37 mm	2193 (25.54)	1648 (25.59)	545 (25.38)	
≥ 60 mm         2174 (25.32)         1631 (25.32)         543 (25.29)           T stage, n (%)         T	38–59 mm	2184 (25.43)	1634 (25.37)	550 (25.62)	
T stage, n (%)         T <tht< th="">         T         T         &lt;</tht<>	≥60 mm	2174 (25.32)	1631 (25.32)	543 (25.29)	
TO         105 (1.22)         77 (1.20)         28 (1.30)           T1         640 (7.45)         471 (7.31)         169 (7.87)           T2         1835 (21.37)         1393 (21.63)         442 (20.59)           T3         1603 (18.67)         1180 (18.32)         423 (19.70)           T4         2870 (33.42)         2165 (33.62)         705 (32.84)           Tx         1394 (17.86)         1180 (18.32)         423 (19.70)           Nstage, n (%)	T stage, n (%)				
TI         640 (7.45)         471 (7.31)         169 (7.87)           T2         1835 (21.37)         1393 (21.63)         442 (20.59)           T3         1603 (18.67)         1180 (18.32)         423 (19.70)           T4         2870 (33.42)         2165 (33.62)         705 (32.84)           Tx         1534 (17.86)         1154 (17.92)         380 (17.70)           N stage, n (%)         890 (10.36)         678 (10.53)         212 (9.87)           N1         519 (6.04)         582 (16.35)         144 (6.71)           N2         4779 (55.65)         3564 (55.34)         1215 (56.59)           N3         1849 (21.53)         1399 (21.72)         450 (20.96)           Nx         505 (6.41)         424 (6.58)         126 (5.87)           Metastatic lesion, n (%)         153 (25.07)         1599 (24.83)         554 (25.80)           Brain         565 (6.58)         419 (6.51)         146 (680)           Lung         729 (8.49)         537 (8.34)         192 (8.94)           Multiple metastases         1527 (17.78)         1147 (17.81)         380 (17.70)           No or unknown         3613 (42.08)         2738 (42.52)         875 (40.75)           Surgery of primary site, n (%)         1147 (17.81) <td>ТО</td> <td>105 (1.22)</td> <td>77 (1.20)</td> <td>28 (1.30)</td>	ТО	105 (1.22)	77 (1.20)	28 (1.30)	
T2     1835 (21.37)     1393 (21.63)     442 (20.59)       T3     1603 (18.67)     1180 (18.32)     423 (19.70)       T4     2870 (33.42)     2165 (33.62)     705 (32.84)       Tx     1534 (17.86)     1154 (17.92)     380 (17.70)       N stage, n (%)       212 (9.87)       N1     519 (6.04)     5.82 (16.35)     144 (6.71)       N2     4779 (55.65)     3564 (55.34)     1215 (56.59)       N3     1849 (21.53)     399 (21.72)     450 (20.96)       Nx     500 (6.11)     426 (58.34)     1215 (56.59)       N3     1849 (21.53)     1399 (21.72)     450 (20.96)       Nx     500 (6.11)     46 (58.7)     159 (4.63)       Metastatic lesion, n (%)     Bone     2153 (25.07)     1599 (24.83)     554 (25.80)       Brain     565 (65.8)     419 (6.51)     146 (68.0)       Lung     729 (8.49)     537 (8.34)     192 (8.94)       Multiple metastases     1527 (17.78)     1147 (17.81)     380 (17.70)       No or unknown     361 (42.08)     2738 (42.52)     875 (40.75)       Surgery of primary site, n (%)     2139 (99.63)     2139 (99.63)       Surgery of metastatic site, n (%)     2139 (99.63)     2139 (99.63)       Surgery of metastatic site, n (%)	T1	640 (7.45)	471 (7.31)	169 (7.87)	
T3         160 (2.6.0)         1180 (18.32)         423 (19.70)           T4         2870 (33.42)         2165 (33.62)         705 (32.84)           Tx         1534 (17.86)         1154 (17.92)         380 (17.70)           N stage, n (%)           212 (9.87)           N1         519 (6.04)         582 (16.35)         144 (6.71)           N2         4779 (55.65)         3564 (55.34)         1215 (56.59)           N3         1849 (21.53)         1399 (21.72)         450 (20.96)           Nx         550 (6.41)         424 (6.58)         126 (5.87)           Metastatic lesion, n (%)           550 (6.58)         419 (6.51)         146 (6.80)           Lung         729 (8.49)         537 (8.34)         192 (8.94)         380 (17.70)           No or unknown         615 (42.08)         2138 (42.52)         875 (40.75)         380 (17.70)           Surgery of primary site, n (%)	T2	1835 (21.37)	1393 (21.63)	442 (20.59)	
T4         2870 (33.42)         165 (33.62)         705 (32.84)           Tx         1534 (17.86)         1154 (17.92)         380 (17.70)           N stage, n (%)	Τ3	1603 (18.67)	1180 (18.32)	423 (19.70)	
Tx         1534 (17.86)         1154 (17.92)         380 (17.70)           N stage, n (%)	T4	2870 (33.42)	2165 (33.62)	705 (32.84)	
N stage, n (%)         View (%)         View (%)           N0         890 (10.36)         678 (10.53)         212 (9.87)           N1         519 (6.04)         5.82 (16.35)         144 (6.71)           N2         4779 (55.65)         3564 (55.34)         1215 (56.59)           N3         1849 (21.53)         1399 (21.72)         450 (20.96)           Nx         0 (6.1)         424 (6.58)         212 (5.87)           Metastatic lesion, n (%)         554 (25.80)         554 (25.80)           Brain         565 (6.58)         419 (6.51)         146 (6.80)           Lung         729 (8.49)         537 (8.34)         192 (8.94)           Multiple metastases         1527 (17.78)         1147 (17.81)         380 (17.70)           No or unknown         613 (42.08)         242.52)         875 (40.75)           Surgery of primary site, n (%)         X         1147 (17.81)         380 (17.70)           No/unknown         8553 (99.60)         6414 (99.60)         2139 (99.63)           Surgery of primary site, n (%)         X         380 (37)         2107 (98.14)	Tx	1534 (17.86)	1154 (17.92)	380 (17.70)	
N0         890 (10.36)         678 (10.53)         212 (9.87)           N1         519 (6.04)         5.82 (16.35)         144 (6.71)           N2         4779 (55.65)         3564 (55.34)         1215 (56.59)           N3         1849 (21.53)         1399 (21.72)         450 (20.96)           Nx         550 (6.41)         424 (6.58)         126 (5.87)           Metastatic lesion, n (%)         550 (6.41)         424 (6.58)         126 (5.87)           Bone         2153 (25.07)         1599 (24.83)         554 (25.80)           Brain         565 (6.58)         419 (6.51)         146 (6.80)           Lung         729 (8.49)         537 (8.34)         192 (8.94)           Multiple metastases         1527 (17.78)         1147 (17.81)         380 (17.70)           No or unknown         3613 (42.08)         2738 (42.52)         875 (40.75)           Surgery of primary site, n (%)         535 (99.60)         6414 (99.60)         2139 (99.63)           Yes         34 (0.40)         26 (0.40)         8 (0.37)           Surgery of metastatic site, n (%)         2107 (98 14)         107 (98 14)	N stage, n (%)	100 ((),100)		500 (17.17.0)	
N1         519 (102)         518 (102)         518 (102)         144 (6.71)           N2         4779 (55.65)         3564 (55.34)         1215 (56.59)           N3         1849 (21.53)         1399 (21.72)         450 (20.96)           Nx         550 (6.41)         424 (6.58)         126 (5.87)           Metastatic lesion, n (%)         550 (6.41)         424 (6.58)         126 (5.87)           Bone         2153 (25.07)         1599 (24.83)         554 (25.80)           Brain         565 (6.58)         419 (6.51)         146 (6.80)           Lung         729 (8.49)         537 (8.34)         192 (8.94)           Multiple metastases         1527 (17.78)         1147 (17.81)         380 (17.70)           No or unknown         3613 (42.08)         2738 (42.52)         875 (40.75)           Surgery of primary site, n (%)         X         2139 (99.63)         8(0.37)           Yes         34 (0.40)         26 (0.40)         8 (0.37)           Surgery of metastatic site, n (%)         X         1107 (98.14)	NO	890 (10 36)	678 (10 53)	212 (9.87)	
N2         4779 (55.65)         3564 (55.34)         1215 (56.59)           N3         1849 (21.53)         1399 (21.72)         450 (20.96)           Nx         550 (6.41)         424 (6.58)         126 (5.87)           Metastatic lesion, n (%)         550 (6.41)         424 (6.58)         126 (5.87)           Metastatic lesion, n (%)         550 (6.41)         424 (6.58)         126 (5.87)           Bone         2153 (25.07)         1599 (24.83)         554 (25.80)           Brain         565 (6.58)         419 (6.51)         146 (6.80)           Lung         729 (8.49)         537 (8.34)         192 (8.94)           Multiple metastases         1527 (17.78)         1147 (17.81)         380 (17.70)           No or unknown         3613 (42.08)         2738 (42.52)         875 (40.75)           Surgery of primary site, n (%)         1147 (17.81)         380 (17.70)           Yes         34 (0.40)         26 (0.40)         8 (0.37)           Surgery of metastatic site, n (%)         26 (0.40)         8 (0.37)	N1	519 (6.04)	5.82 (16.35)	144 (6 71)	
N2       N3       1849 (21.53)       1399 (21.72)       450 (20.96)         Nx       550 (6.41)       424 (6.58)       126 (5.87)         Metastatic lesion, n (%)       500       554 (25.80)       554 (25.80)         Bone       2153 (25.07)       1599 (24.83)       554 (25.80)         Brain       565 (6.58)       419 (6.51)       146 (6.80)         Lung       729 (8.49)       537 (8.34)       192 (8.94)         Multiple metastases       1527 (17.78)       1147 (17.81)       380 (17.70)         No or unknown       3613 (42.08)       2738 (42.52)       875 (40.75)         Surgery of primary site, n (%)       1       2139 (99.63)       8 (0.37)         Yes       34 (0.40)       26 (0.40)       8 (0.37)         Surgery of metastatic site, n (%)       2107 (98 14)       107 (98 14)	N2	4779 (55 65)	3564 (55 34)	1215 (56 59)	
Nx         550 (6.41)         424 (6.58)         156 (c.11.2)           Metastatic lesion, n (%)         550 (6.41)         424 (6.58)         126 (5.87)           Metastatic lesion, n (%)         550 (6.50)         1599 (24.83)         554 (25.80)           Bone         2153 (25.07)         1599 (24.83)         554 (25.80)           Brain         565 (6.58)         419 (6.51)         146 (6.80)           Lung         729 (8.49)         537 (8.34)         192 (8.94)           Multiple metastases         1527 (17.78)         1147 (17.81)         380 (17.70)           No or unknown         3613 (42.08)         2738 (42.52)         875 (40.75)           Surgery of primary site, n (%)         2         2         26 (0.40)         2139 (99.63)           Yes         34 (0.40)         26 (0.40)         8 (0.37)         2107 (98 14)	N3	1849 (21 53)	1399 (21 72)	450 (20.96)	
Number         Part (2007)         Part (2007) <t< td=""><td>Nx</td><td>550 (6 41)</td><td>424 (6 58)</td><td>126 (5.87)</td></t<>	Nx	550 (6 41)	424 (6 58)	126 (5.87)	
Bone         2153 (25.07)         1599 (24.83)         554 (25.80)           Brain         565 (6.58)         419 (6.51)         146 (6.80)           Lung         729 (8.49)         537 (8.34)         192 (8.94)           Multiple metastases         1527 (17.78)         1147 (17.81)         380 (17.70)           No or unknown         3613 (42.08)         2738 (42.52)         875 (40.75)           Surgery of primary site, n (%)         2139 (99.63)         414 (99.60)         2139 (99.63)           Yes         34 (0.40)         26 (0.40)         8 (0.37)           Surgery of metastatic site, n (%)         2700 (98.14)         2107 (98.14)	Metastatic lesion n (%)	555 (011)	.2 . (0.00)	.20 (3.67)	
Brain       565 (6.58)       419 (6.51)       146 (6.80)         Lung       729 (8.49)       537 (8.34)       192 (8.94)         Multiple metastases       1527 (17.78)       1147 (17.81)       380 (17.70)         No or unknown       3613 (42.08)       2738 (42.52)       875 (40.75)         Surgery of primary site, n (%)       748       2139 (99.63)       2139 (99.63)         Yes       34 (0.40)       26 (0.40)       8 (0.37)         Surgery of metastatic site, n (%)       537 (99.61)       6309 (97.97)       2107 (98.14)	Bone	2153 (25.07)	1599 (24.83)	554 (25 80)	
Lung         729 (8.49)         537 (8.34)         192 (8.94)           Multiple metastases         1527 (17.78)         1147 (17.81)         380 (17.70)           No or unknown         3613 (42.08)         2738 (42.52)         875 (40.75)           Surgery of primary site, n (%)          2139 (99.63)         192 (8.94)           Yes         34 (0.40)         26 (0.40)         8 (0.37)           Surgery of metastatic site, n (%)          2107 (98.14)	Brain	565 (6 58)	419 (6 51)	146 (6.80)	
Multiple metastases       1527 (17.78)       1147 (17.81)       380 (17.70)         No or unknown       3613 (42.08)       2738 (42.52)       875 (40.75)         Surgery of primary site, n (%)       748       2139 (99.63)       2139 (99.63)         Yes       34 (0.40)       26 (0.40)       8 (0.37)         Surgery of metastatic site, n (%)       748       749       740         Not/unknown       8416 (98.01)       6309 (97.97)       2107 (98.14)	lung	729 (849)	537 (8 34)	192 (8.94)	
No or unknown     3613 (42.08)     2738 (42.52)     875 (40.75)       Surgery of primary site, n (%)      2139 (99.63)       Yes     34 (0.40)     26 (0.40)     8 (0.37)       Surgery of metastatic site, n (%)          Not/unknown     8416 (98.01)     6309 (97.97)     2107 (98.14)	Multiple metastases	1527 (1778)	1147 (17.81)	380 (17 70)	
Surgery of primary site, n (%)     Eris (12.62)     Eris (12.62)       No/unknown     8553 (99.60)     6414 (99.60)     2139 (99.63)       Yes     34 (0.40)     26 (0.40)     8 (0.37)       Surgery of metastatic site, n (%)     500 (97.97)     2107 (98.14)	No or unknown	3613 (42.08)	2738 (42 52)	875 (40 75)	
No/unknown         8553 (99.60)         6414 (99.60)         2139 (99.63)           Yes         34 (0.40)         26 (0.40)         8 (0.37)           Surgery of metastatic site, n (%)         500 (97.97)         2107 (98.14)	Surgery of primary site in (%)	55.5 (12.00)		0.0(10.70)	
Yes         34 (0.40)         26 (0.40)         8 (0.37)           Surgery of metastatic site, n (%)         8416 (98.01)         6309 (97.97)         2107 (98.14)	No/unknown	8553 (99.60)	6414 (99 60)	2139 (99 63)	
Surgery of metastatic site, n (%)         8416 (98.01)         6309 (97.97)         2107 (98.14)	Yes	34 (0 40)	26 (0.40)	8 (0 37)	
Not/unknown 8416 (98.01) 6309 (97.97) 2107 (98.14)	Surgery of metastatic site in (%)	5 1 (0.10)	20 (0.10)	0 (0.57)	
	Not/unknown	8416 (98.01)	6309 (97 97)	2107 (98 14)	

Total (n=8,587)		Training set ( <i>n</i> = 6,440)	Testing set ( <i>n</i> = 2,147)
Yes	171 (1.99)	131 (2.03)	40 (1.86)
Chemotherapy, n (%)			
Not/unknown	3059 (35.62)	2292 (35.59)	767 (35.72)
Yes	5528 (64.38)	4148 (64.41)	1380 (64.28)
Radiotherapy, n (%)			
Not/unknown	6216 (72.39)	4664 (72.42)	1552 (72.29)
Yes	2371 (27.61)	1776 (27.58)	595 (27.71)
CSS	0.0179	0.0174	0.0196
OS	1.79%	1.74%	1.96%

Table 1 (continued)

SCLC small cell lung cancer, NOS not otherwise specified, Tx not specific known T stage, Nx not specific known N stage, CSS cancer specific survival, OS overall survival

0.5 (no discrimination) to 1.0 (perfect discrimination). The higher the value between 0.5 and 1, the stronger the resolution of the nomogram. Calibration measures to what degree the predicted probabilities are close to actual outcomes. Calibration plots of the nomogram for 1- and 2-year CSS and OS were performed in the training set and the testing set. The prediction models were also verified by 5-fold cross validation. The 5-fold cross-validation was done to make the results more realistic and to avoid chance. The data set was divided into five groups by a 5-fold cross-validation operation. For each training session, one set was used as the validation set and the remaining four sets were used as the training set. After addressing the ability of the nomogram, we used DCA to test the reliability of the model, which was a method for evaluating alternative diagnostic and prognostic strategies that have advantages over other commonly used measures and techniques. If the threshold probability of net benefits is unpractical, then the applicability of a well-performing model may be limited, meaning that the benefits of the new prediction model will be less than the benefits of existing tools, and may even be detrimental. The prediction models with and without chemotherapy for predicting CSS and OS in SCLC patients with liver metastasis were conducted and were compared with the prediction models. Data analysis used R software version 4.1.2 (R Foundation). All tests were two-tailed and P < 0.05 was considered statistically significant,

# Results

## Characteristics of the included patients

In total, 8,587 eligible patients, who were diagnosed as SCLC patients with liver metastasis from 2010 to 2015 were identified in the SEER database. The flow chart of patient's selection is shown in Fig. 1. Among them, 154 patients experienced CSS, and 154 patients experienced OS. The median follow-up time was 3 months. For all patients, there were 3,770 (43.90%) patients with age  $\leq 65$  years and 4,817 (56.10%) patients with age>65 years. As for the race, the majority of patients (88.84%) were white. With respect to the primary site, most of them were located in the upper lobe. The majority of patients were classified as T4 (33.42%) and N2 (55.65%). The baseline characteristics of the patients are presented in Table 1.

# Identification of the predictive factors for CSS and OS in SCLC patients with liver metastasis

Identifications of factors associated with CSS and OS are shown in Table 2. The results demonstrated that age>65 years (HR: 1.303, 95% CI: 1.238-1.372, *P*<0.001), being male (HR: 1.113, 95% CI: 1.057–1.171, P<0.001), being married (HR: 0.907, 95% CI: 0.863-0.955, P<0.001), Nx stage (HR: 1.264, 95% CI: 1.115-1.433, P < 0.001, FDR-adjusted P < 0.001), lung metastases (HR: 1.189, 95% CI: 1.075–1.316, P=0.001, FDR-adjusted *P*=0.004), multiple metastases (HR: 1.115, 95% CI: 1.031–1.206, P=0.007 FDR-adjusted P=0.021), surgery of metastatic site (HR: 0.927, 95% CI: 0.776-1.109, P=0.407), chemotherapy (HR: 0.232, 95% CI: 0.219-0.246, P<0.001), and radiotherapy (HR: 0.627, 95% CI: 0.593–0.664, P < 0.001) were associated with CSS in SCLC patients with liver metastasis. Age > 65 years, being male, being married, Nx stage, lung metastases, multiple metastases, no metastases/unknown, surgery of metastatic site, chemotherapy, and radiotherapy were associated with OS in SCLC patients with liver metastasis.

# Development of prediction models for CSS and OS in SCLC patients with liver metastasis

We developed two nomograms respectively for CSS and OS. Each of the variables was given a point according to

Variables	CSS			OS			
	HR (95% CI)	Р	FDR-adjusted P	HR (95% CI)	Р	FDR-adjusted P	
Age, n (%), years							
≤65	1			1			
>65	1.303 (1.238–1.372)	< 0.001		1.325 (1.261–1.393)	< 0.001		
Gender, n (%)							
Female	1			1			
Male	1.113 (1.057–1.171)	< 0.001		1.135 (1.080–1.192)	< 0.001		
Race, n (%)							
Black	1			1			
White	1.068 (0.970-1.177)	0.178		1.050 (0.956–1.153)	0.305		
Others	0.971 (0.822–1.147)	0.733		0.973 (0.829–1.143)	0.741		
Marital status, n (%)							
Others	1			1			
Married	0.907 (0.863–0.955)	< 0.001		0.896 (0.853–0.942)	< 0.001		
Primary sites, n (%)				, , ,			
Multiple sites	1			1			
Upper lobe	0.932 (0.756-1.148)	0.508		0.935 (0.762–1.147)	0.518		
Middle lobe	0.877 (0.683–1.126)	0 304		0.894 (0.701–1.141)	0369		
l ower lobe	0.916 (0.740–1.134)	0.420		0.931 (0.756–1.146)	0.500		
Main bronchus	0.894 (0.718–1.113)	0.315		0.890 (0.718–1.103)	0.286		
NOS	1 087 (0 879–1 345)	0.441		1 101 (0 894–1 356)	0.366		
Tumor size n (%)		0.111			0.000		
0-24 mm	1			1			
25-37 mm	1 025 (0 954–1 102)	0.498		1 030 (0 960–1 106)	0 404		
38–59 mm	1.018 (0.947-1.094)	0.634		1.021 (0.951–1.095)	0.572		
>60 mm	0.944 (0.878–1.015)	0.120		0.948 (0.883-1.017)	0.135		
T n (%)	0.911 (0.070 1.013)	0.120		0.910 (0.003 1.017)	0.155		
то	1			1			
T1	0925 (0718-1191)	0 544		0 906 (0 710–1 155)	0.474		
Т2	1.018 (0.800-1.295)	0.885		0.981 (0.779–1.236)	0.873		
T3	1.068 (0.839–1.360)	0.594		1.034 (0.820-1.305)	0.775		
Тл	1.000 (0.035 1.300)	0.554		0.972 (0.773_1.203)	0.775		
Tv	1.004 (0.7.51 1.274)	0.276		1 136 (0 900_1 433)	0.284		
N n (%)	1.105 (0.510 1.105)	0.200		1.150 (0.500 1.155)	0.201		
NO	1			1			
N1	0 959 (0 841-1 093)	0.528	0.628	' 0 945 (0 832–1 074)	0 387	0 592	
N2	0.979 (0.899–1.066)	0.520	0.628	0.978 (0.900-1.062)	0.507	0.592	
N3	0.973 (0.839_1.000)	0.020	0.201	0.976 (0.900 1.002)	0.552	0.321	
Ny	1 264 (1 115-1 433)	< 0.001	< 0.001	1 267 (1 121_1 431)	< 0.001	< 0.001	
Metastatic sites n (%)	1.204 (1.115 1.455)	< 0.001	< 0.001	1.207 (1.121 1.431)	< 0.001	< 0.001	
Bone	1			1			
Brain	1 116 (1 000 1 247)	0.051	0.051	1 110 (0 006 1 227)	0.050	0.050	
Lung	1.110 (1.000 1.247)	0.001	0.004	1.110 (0.220 1.237)	< 0.000	< 0.001	
Multiple metastases	1.109 (1.075-1.510)	0.001	0.004	1.200 (1.032-1.331)	0.001	0.012	
No motostasos/unknown	1.113 (1.031-1.200)	0.007	0.021	1.087 (1.030-1.207)	0.004	0.012	
NO MERCASIASES/ UNKNOWN	1.000 (1.002-1.139)	0.042	0	1.007 (1.021-1.137)	0.009	0.010	
Surgery of primary site, n (%)							
Not/unknown	1			1			
Yes	0.652 (0.440–0.966)	0.033		0.619 (0.418-0.916)	0.017		

# Table 2 Identifications of factors associated with CSS and OS in SCLC patients with liver metastasis

# Table 2 (continued)

Variables	CSS	CSS			OS		
	HR (95% CI)	Р	FDR-adjusted P	HR (95% CI)	Р	FDR-adjusted P	
Surgery of metastatic site, n	n (%)						
Not/unknown	1			1			
Yes	0.927 (0.776–1.109)	0.407		0.938 (0.789–1.116)	0.471		
Chemotherapy, n (%)							
Not/unknown	1			1			
Yes	0.232 (0.219-0.246)	< 0.001		0.225 (0.213–0.238)	< 0.001		
Radiotherapy, n (%)							
Not/unknown	1			1			
Yes	0.627 (0.593–0.664)	< 0.001		0.616 (0.583–0.651)	< 0.001		

SCLC small cell lung cancer, NOS not otherwise specified, CSS cancer specific survival, HR hazard ratio, CI confidence interval, FDR false-discovery rate, OS overall survival, Tx not specific known T stage, Nx not specific known N stage

the HR. Then, by adding the total score of each variable and locating the score on the total points scale, the 1- and 2-year CSS and OS could be obtained. The nomograms containing independent predictive factors for predicting 1- and 2-year CSS and OS prediction of SCLC patients with liver metastasis are shown in Figs. 2 and 3.

# Performance of the prediction models for CSS and OS in SCLC patients with liver metastasis

In the training set, the C-index for CSS predicted by the prediction model was 0.724 (95% CI: 0.716-0.731), whereas the C-index for OS was 0.732 (95% CI: 0.724-0.739) (Table 3). In the testing set, the C-index for CSS



0.2 0.15 0.1

Fig. 2 The nomogram containing independent predictive factors for the 1- and 2-year CSS and OS prediction of SCLC patients with liver metastasis; CSS: cancer-specific survival; SCLC: small-cell lung cancer

Dointa	0	10	20	30	40	50	60	70	80	90	100
romis		~ (5									<u> </u>
Age	<=65	>05 	1.								
Sex	Femal	•Ma	le								
Marital status	ں نیسے Marție	ed									
NX stage		es									
Lung metastases	Y o International No	es									
Multiple metastases	No										
No/unknown metastases	Yes	10	N								
Surgery of primary site	Yes										No
Chemotherapy	Yes		No								
Radiation	Yes										
Total Points	0	20	40	60	80	100	120	140	160	180	200
1 year survival probability	0.4	0.35 0.3	0.25 0.2	0.15 0.1	0	ר .05					
2 year survival probability	C	0.15 0.1	0.05								

Fig. 3 The nomogram containing independent predictive factors for the 1- and 2-year OS prediction of SCLC patients with liver metastasis; OS: overall survival; SCLC: small-cell lung cancer

Table 3 C-indexes of the prediction models for CSS and OS in SCLC patients with liver m	etastasis
---	-----------

Models	C-index (95% Cl)	C-index (95% Cl)							
	CSS		OS						
	Training set	Testing set	Training set	Testing set					
Total model	0.724 (0.716-0.731)	0.734 (0.722–0.747)	0.732 (0.724–0.739)	0.739 (0.727–0.751)					
1-year model	0.727 (0.719–0.734)	0.737 (0.724–0.749)	0.734 (0.727-0.742)	0.742 (0.730–0.754)					
2-year model	0.724 (0.717–0.731)	0.735 (0.723–0.747)	0.732 (0.725–0.739)	0.739 (0.727–0.751)					

SCLC small cell lung cancer, CSS cancer specific survival, OS overall survival, CI confidence interval

and OS were 0.734 (95% CI: 0.722–0.747), and 0.739 (95% CI: 0.727–0.751), respectively. The C-index of the prediction model for predicting 1-year CSS, and 2-year CSS was 0.727 (95% CI: 0.719–0.734), and 0.724 (95% CI: 0.717–0.731), respectively, in the training set. The C-index of the prediction model for predicting 1-year OS, and 2-year OS was 0.734 (95% CI: 0.727–0.742), and 0.732 (95% CI: 0.725–0.739), respectively, in the training set. C-indexes of the prediction models for CSS and OS

in SCLC patients with liver metastasis are presented in Table 3. The 5-fold cross-validation results are shown in Table 4, which showed a similar performance as the prediction models conducted. Calibration and DCA curves show that the nomogram has good predictive accuracy and value. The results of calibration are shown in Fig. 4. The DCA curve for predicting 1- and 2-year CSS and OS prediction of SCLC patients with liver metastasis is presented in Fig. 5.

Table 4 The 5-fold cross-validation results of the performance of the prediction models for CSS and OS in SCLC patients with liver metastasis

5-fold cross-validation	C-index (95% Cl)								
	CSS		OS						
	Training set	Validation	Training set	Validation					
First fold	0.724 (0.716–0.732)	0.719 (0.703–0.736)	0.732 (0.724–0.739)	0.727 (0.711–0.743)					
Second fold	0.725 (0.717–0.733)	0.717 (0.701–0.734)	0.732 (0.724–0.739)	0.730 (0.715–0.746)					
Third fold	0.722 (0.714–0.730)	0.728 (0.712-0.744)	0.731 (0.723–0.739)	0.732 (0.717–0.748)					
Forth fold	0.723 (0.715–0.731)	0.725 (0.709–0.742)	0.731 (0.723-0.739)	0.732 (0.716–0.748)					
Fifth fold	0.723 (0.715–0.732)	0.722 (0.706–0.738)	0.735 (0.727–0.743)	0.729 (0.713–0.745)					

SCLC small cell lung cancer, CSS cancer specific survival, OS overall survival, CI confidence interval

# Comparisons of prediction models with and without chemotherapy for predicting CSS and OS in SCLC patients with liver metastasis

The nomogram indicated that chemotherapy carries significantly more importance compared to other variables, thereby, comparisons of prediction models with and without chemotherapy for predicting CSS and OS in SCLC patients with liver metastasis were performed. The C-index of the prediction models with only chemotherapy was 0.687 (95% CI: 0.681–0.693) for predicting CSS in the training set, and the C-index of the prediction models without chemotherapy was 0.613 (95% CI: 0.604–0.621) (Tables 5 and 6).

# Discussion

In this study, prediction models were constructed to predict the CSS and OS in SCLC patients with liver metastases. The results showed that the prediction models exhibited good performance with the C-indexes being 0.725 of CSS in SCLC patients with liver metastases and OS being 0.732. Our result indicated that age, the male, married, N stage, other metastases, chemotherapy, and radiotherapy were independent predictive factors affecting the CSS and OS of SCLC patients with liver metastasis.

A number of existing nomograms have been conducted for patients with SCLC. However, most of these models, have been developed for different stages of diagnosed SCLC, and none have included liver metastasis. In a single institution study by Xiao et al., a nomogram was constructed to predict the 3-year and 5-year OS for SCLC [18]. However, the c-index of the nomogram (= 0.60) was not high, and data on T, N, and M information were missing. Xie et al. [19] established two nomograms by classifying patients as limited or extensive SCLC, without including tumor pathological information such as tumor size. Pan et al. [20] established a nomogram for SCLC, using only a small sample size of resected SCLC patients. Gao et al. establish a prediction model for extensive-stage SCLC patients with different metastatic sites [12]. However, the C-index was 0.66. We first used the SEER database to identify independent factors for CSS and OS, and establish the prediction models for the survival of SCLC with liver metastasis. The C index of nomograms is greater than 0.7, indicating that it has sufficient discriminatory power. The DCA results showed that the nomogram we established had good clinical utility. The nomogram prediction model of SCLC liver metastasis may help to clarify the treatment stratification and efficacy evaluation of SCLC liver metastasis. Using our prediction models, researchers and clinicians could easily predict the CSS and OS of each SCLC patient with liver metastasis.

Previous studies have shown that advanced age is a poor prognostic factor for SCLC patients [9, 13, 21]. Our study suggests that elderly SCLC patients diagnosed with liver metastases have unfavorable CSS and OS. The increased risk may be associated with degenerative changes in various aspects of organ function and with an increased incidence of comorbidities [22]. In addition, older patients may be more susceptible to toxic reactions caused by systemic treatment, while younger patients may be in better health and better able to tolerate the side effects of chemotherapy and radiotherapy [23]. In this study, being unmarried and male are poor prognostic factors for SCLC patients with liver metastasis. Unmarried patients lack the psychological and economic support of their spouses, which leads to poor prognosis [24]. In terms of treatment methods, radiotherapy and chemotherapy are common treatment methods for SCLC [25]. Chemotherapy, as the main treatment for SCLC, has been proven to prolong survival time [26]. Gao et al. [12] also reported that chemotherapy was a predictive variable of prognosis for



Fig. 4 The calibration curve for the 1- and 2-year CSS and OS prediction of SCLC patients with liver metastasis; A 1-year CSS in the training set; B 2-year CSS in the training set; C 1-year OS in the training set; D 2-year OS in the training set; E 1-year CSS in the test set; F 2-year CSS in the test set; G 1-year OS in the test set; CSS: cancer-specific survival; OS: overall survival; SCLC: small-cell lung cancer



Fig. 5 The DCA curve for the 1- and 2-year CSS and OS prediction of SCLC patients with liver metastasis; **A** 1-year CSS in the training set; **B** 2-year CSS in the training set; **C** 1-year OS in the training set; **D** 2-year OS in the training set. In the figure, the abscissa is the threshold probability, the ordinate is the net benefit rate. The horizontal green one indicates that all samples are negative and all are not treated, with a net benefit of zero. The oblique red one indicates that all samples are positive. The net benefit is a backslash with a negative slope (blue). DCA: decision curve analysis; CSS: cancer-specific survival; OS: overall survival; SCLC: small-cell lung cancer

extensive-stage SCLC patients. Radiotherapy is usually considered as a palliative local treatment, mainly used for symptomatic treatment [27]. In this study, radiotherapy was significantly associated with prolonged CSS and OS of SCLC patients with liver metastases. Selecting a more precise treatment for patients, avoiding wasting healthcare resources, and guiding clinicians in their treatment decisions is of importance.

At present, research into SCLC patients with liver metastases is limited or only has focused on a special type of lung cancer patient. Combined with the fact that liver metastasis of SCLC patients is relatively high and liver metastasis has a negative impact on prognosis, research on liver metastasis of SCLC patients is very necessary and urgent. To the best of our knowledge, this is the first study that constructed nomograms to predict the CSS and OS of SCLC patients with liver metastasis. In this paper, based on the SEER database, a large number of related information of SCLC patients with liver metastasis was extracted to make the study more widely applicable. Second, oncologists and patients alike want reliable prognostic information for each patient. One of the tools that can achieve this is the nomogram, which creates a simple graphical representation of a statistical prediction model to generate numerical probabilities of clinical events. We established not only the OS prediction model Table 5 Performance of the prediction models with and without chemotherapy for predicting CSS and OS in SCLC patients with liver metastasis

Models	C-index (95% Cl)							
	CSS		OS					
	Training set	Testing set	Training set	Testing set				
Total model	0.724 (0.716–0.731)	0.734 (0.722–0.747)	0.732 (0.724–0.739)	0.739 (0.727–0.751)				
Only chemotherapy	0.687 (0.681–0.693)	0.692 (0.682-0.703)	0.692 (0.686–0.698)	0.692 (0.682–0.703)				
Total model without chemo- therapy	0.613 (0.604–0.621)	0.624 (0.610–0.639)	0.619 (0.610–0.627)	0.624 (0.610–0.639)				

SCLC small cell lung cancer, CSS cancer specific survival, OS overall survival, CI confidence interval

**Table 6** Comparisons of prediction models with and without chemotherapy for predicting CSS and OS in SCLC patients with liver metastasis

Models	CSS	OS
	Ρ	Р
Total model vs Only chemotherapy	< 0.001	< 0.001
Total model vs Total model without chemo- therapy	< 0.001	< 0.001

SCLC small cell lung cancer, CSS cancer specific survival, OS overall survival

of liver metastasis in SCLC patients, but also the CSS model of liver metastasis in SCLC patients, which can be used by clinicians to predict the OS and CSS of liver metastasis in SCLC patients respectively, thus, improving the survival of SCLC patients with liver metastasis.

The limitations of this study should be acknowledged. First, this study is a retrospective study and has its own limitations, which may have influenced our results. Second, due to the lack of information on living environment, lifestyle, adjuvant therapy and commodities, it is impossible to consider all prognostic factors comprehensively, which is also an inherent limitation of the SEER research. Third, no external validation was performed to further evaluate this nomogram, possibly limiting the generalization of our model. Future well-designed prospective studies with large sample sizes are needed to validate the results of this study.

## Conclusion

In this study, the prediction models showed excellent predictive performance for predicting survival of SCLC patients with liver metastasis. Clinicians can predict CSS and OS of SCLC patients with liver metastasis by simply incorporating prognostic factors into a nomogram. Early identification of high-risk groups with poor prognoses can enable personalized intervention, improve patient survival.

#### Abbreviations

SCLC	Small cell lung cancer
OS	Overall survival
CSS	Cancer-specific survival
SEER	Surveillance, Epidemiology, and End Results
ICD-O-3	International Classification of Diseases for Oncology third edition
NOS	Not otherwise specified
Mean±SD	Mean ± standard deviation
ANOVA	Analysis of one-way variance
HR	Hazard ratio
CI	Confidence interval

## **Supplementary Information**

The online version contains supplementary material available at https://doi. org/10.1186/s12890-023-02832-7.

Additional file 1.

#### Acknowledgements

Not applicable.

#### Authors' contributions

QL, YZ, CW and ZX designed the study. QL and YZ wrote the manuscript. YM collected, analyzed, and interpreted the data. CW and HS critically reviewed, edited, and approved the manuscript. All authors read and approved the final manuscript.

#### Funding

National Natural Science Foundation of China (No. 81803997); Natural Science Foundation for Youth of Nanjing University of Chinese Medicine (No. NZY81803997).

#### Availability of data and materials

All data relevant to the study are included in the article is available from SEER database, https://seer.cancer.gov/.

#### Declarations

#### Ethics approval and consent to participate

Since the clinical data in this study were collected from a publicly available database, there were no local or state ethical issues. In addition, because this retrospective study was based on public data from the SEER database, informed consent was not required. All methods were performed in accordance with the relevant guidelines and regulations.

#### **Consent for publication**

Not applicable.

#### **Competing interests**

The authors declare no competing interests.

# Author details

<sup>1</sup>College of Traditional Chinese Medicine & College of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, No. 138 Xianlin Avenue, Qixia District, Nanjing 210023, P. R. China. <sup>2</sup>Department of Science and Technology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, P. R. China.

# Received: 19 June 2023 Accepted: 27 December 2023 Published online: 04 January 2024

## References

- Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584–90.
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
- Calles A, Aguado G, Sandoval C, Álvarez R. The role of immunotherapy in small cell lung cancer. Clin Transl Oncol. 2019;21(8):961–76.
- 4. Tian Y, Zhai X, Han A, Zhu H, Yu J. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. J Hematol Oncol. 2019;12(1):67.
- Li J, Zhu H, Sun L, Xu W, Wang X. Prognostic value of site-specific metastases in lung cancer: a population based study. J Cancer. 2019;10(14):3079–86.
- Cai H, Wang H, Li Z, Lin J, Yu J. The prognostic analysis of different metastatic patterns in extensive-stage small-cell lung cancer patients: a large population-based study. Future Oncol. 2018;14(14):1397–407.
- Nakazawa K, Kurishima K, Tamura T, Kagohashi K, Ishikawa H, Satoh H, Hizawa N. Specific organ metastases and survival in small cell lung cancer. Oncol Lett. 2012;4(4):617–20.
- Combs SE, Hancock JG, Boffa DJ, Decker RH, Detterbeck FC, Kim AW. Bolstering the case for lobectomy in stages I, II, and IIIA small-cell lung cancer using the National Cancer Data Base. J Thorac Oncol. 2015;10(2):316–23.
- Wang Y, Pang Z, Chen X, Yan T, Liu J, Du J. Development and validation of a prognostic model of resectable small-cell lung cancer: a large population-based cohort study and external validation. J Transl Med. 2020;18(1):237.
- Zou J, Guo S, Xiong MT, Xu Y, Shao J, Tong Z, Zhang P, Pan L, Peng A, Li X. Ageing as key factor for distant metastasis patterns and prognosis in patients with extensive-stage small cell lung cancer. J Cancer. 2021;12(6):1575–82.
- Cheng Y, Wang Q, Li K, Shi J, Wu L, Han B, Chen G, He J, Wang J, Qin H, et al. Anlotinib for patients with small cell lung cancer and baseline liver metastases: a post hoc analysis of the ALTER 1202 trial. Cancer Med. 2022;11(4):1081–7.
- Gao H, Dang Y, Qi T, Huang S, Zhang X. Mining prognostic factors of extensive-stage small-cell lung cancer patients using nomogram model. Medicine. 2020;99(33):e21798.
- Liu J, Zhou H, Zhang Y, Fang W, Yang Y, Hong S, Chen G, Zhao S, Chen X, Zhang Z, et al. Cause-specific death assessment of patients with stage I small-cell lung cancer: a competing risk analysis. Future Oncol. 2019;15(21):2479–88.
- 14. Veronesi G, Bottoni E, Finocchiaro G, Alloisio M. When is surgery indicated for small-cell lung cancer? Lung Cancer. 2015;90(3):582–9.
- Li J, Zheng Q, Zhao X, Zhao J, An T, Wu M, Wang Y, Zhuo M, Zhong J, Yang X, et al. Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis. BMC Cancer. 2020;20(1):793.
- Cronin KA, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer. 2014;120(Suppl 23):3755–7.
- Wu XQ, Li JY, Du WJ. Causes of death following small cell lung cancer diagnosis: a population-based analysis. BMC Pulm Med. 2022;22(1):262.
- Xiao HF, Zhang BH, Liao XZ, Yan SP, Zhu SL, Zhou F, Zhou YK. Development and validation of two prognostic nomograms for predicting survival in patients with non-small cell and small cell lung cancer. Oncotarget. 2017;8(38):64303–16.

- Xie D, Marks R, Zhang M, Jiang G, Jatoi A, Garces YI, Mansfield A, Molina J, Yang P. Nomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers. J Thorac Oncol. 2015;10(8):1213–20.
- Pan H, Shi X, Xiao D, He J, Zhang Y, Liang W, Zhao Z, Guo Z, Zou X, Zhang J, et al. Nomogram prediction for the survival of the patients with small cell lung cancer. J Thorac Dis. 2017;9(3):507–18.
- Lara JD, Brunson A, Riess JW, Kelly K, Lara PN Jr, Gandara DR. Clinical predictors of survival in young patients with small cell lung cancer: results from the California Cancer Registry. Lung Cancer. 2017;112:165–8.
- Aarts MJ, Aerts JG, van den Borne BE, Biesma B, Lemmens VE, Kloover JS. Comorbidity in patients with small-cell lung cancer: trends and prognostic impact. Clin Lung Cancer. 2015;16(4):282–91.
- Chen RC, Royce TJ, Extermann M, Reeve BB. Impact of age and comorbidity on treatment and outcomes in elderly cancer patients. Semin Radiat Oncol. 2012;22(4):265–71.
- 24. Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, Graham PL, Choueiri TK, Hoffman KE, Martin NE, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013;31(31):3869–76.
- Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?-a review. Transl Lung Cancer Res. 2016;5(1):26–38.
- 26. Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, Karlin DA, Faoro L, Scappaticci FA, Socinski MA. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011;29(16):2215–22.
- Nieder C, Tollali T, Yobuta R, Reigstad A, Flatoy LR, Pawinski A. Palliative thoracic radiotherapy for lung cancer: what is the impact of total radiation dose on survival? J Clin Med Res. 2017;9(6):482–7.

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

